(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...

The prognosis for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements is poor, and treatment options are limited. In a phase II study of these patients, the overall complete response ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Analysis of >40 subtypes of lymphoid blood cancer tracked by the UK Haematological Malignancy Research Network reveals wide incidence and survival variation, but distinct gains in survival since ...

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Peripheral eosinophilia as a potential biomarker of response and immune-related adverse events in patients with gastrointestinal tumors treated with immune checkpoint inhibitors: A single-center ...

Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...

A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...